300313 *ST天山生物
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)101.551-225.890-30.069-33.810-21.075
总资产报酬率 ROA (%)-3.189-23.410-6.793-8.700-4.180
投入资产回报率 ROIC (%)-9.593-55.083-13.037-14.583-8.625

边际利润分析
销售毛利率 (%)18.352-5.23016.98614.1667.089
营业利润率 (%)-12.180-44.576-13.572-36.988-26.047
息税前利润/营业总收入 (%)-0.352-38.280-6.278-21.879-13.434
净利润/营业总收入 (%)-18.101-48.748-16.061-41.952-28.149

收益指标分析
经营活动净收益/利润总额(%)160.96673.16880.28973.521117.534
价值变动净收益/利润总额(%)-20.099-5.374-15.06926.411-2.921
营业外收支净额/利润总额(%)4.9623.2553.3407.3241.479

偿债能力分析
流动比率 (X)0.3130.3210.4840.5210.633
速动比率 (X)0.2100.2260.1680.2810.527
资产负债率 (%)100.76897.71177.16271.71471.353
带息债务/全部投入资本 (%)90.63585.08150.43447.53553.899
股东权益/带息债务 (%)-16.828-5.12680.67495.85076.713
股东权益/负债合计 (%)-4.770-1.55825.55935.29036.558
利息保障倍数 (X)-0.028-4.910-0.809-1.213-1.033

营运能力分析
应收账款周转天数 (天)66.27034.04125.98482.71561.330
存货周转天数 (天)101.294113.040199.698228.050133.930